Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK2260 in Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Carcinoma, or Head and Neck Squamous Cell Carcinoma
NCT06248411Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Nov 2023
- Primary completion
- Oct 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KK2260 in solid tumor, Esophageal Squamous Cell Carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Events at 1 year and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
KK2260
03
Conditions
solid tumorEsophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06248411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248411.